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New gorilla adenovirus vaccine 
vectors induce potent immune responses 
and protection in a mouse malaria model
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Abstract 
Background: A DNA-human Ad5 (HuAd5) prime-boost malaria vaccine has been shown to protect volunteers 
against a controlled human malaria infection. The potency of this vaccine, however, appeared to be affected by the 
presence of pre-existing immunity against the HuAd5 vector. Since HuAd5 seroprevalence is very high in malaria-
endemic areas of the world, HuAd5 may not be the most appropriate malaria vaccine vector. This report describes the 
evaluation of the seroprevalence, immunogenicity and efficacy of three newly identified gorilla adenoviruses, GC44, 
GC45 and GC46, as potential malaria vaccine vectors.
Results: The seroprevalence of GC44, GC45 and GC46 is very low, and the three vectors are not efficiently neutralized 
by human sera from Kenya and Ghana, two countries where malaria is endemic. In mice, a single administration of 
GC44, GC45 and GC46 vectors expressing a murine malaria gene, Plasmodium yoelii circumsporozoite protein (PyCSP), 
induced robust PyCSP-specific T cell and antibody responses that were at least as high as a comparable HuAd5-
PyCSP vector. Efficacy studies in a murine malaria model indicated that a prime-boost regimen with DNA-PyCSP and 
GC-PyCSP vectors can protect mice against a malaria challenge. Moreover, these studies indicated that a DNA-GC46-
PyCSP vaccine regimen was significantly more efficacious than a DNA-HuAd5-PyCSP regimen.
Conclusion: These data suggest that these gorilla-based adenovectors have key performance characteristics 
for an effective malaria vaccine. The superior performance of GC46 over HuAd5 highlights its potential for clinical 
development.
Keywords: Genetic, Molecular, Vaccine, Malaria, Adenovector, Adenovirus, Gorilla, Non-human primate,  
Single-administration, Efficacy
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Background
Malaria, HIV1 and TB kill more than four million peo-
ple every year [1]. Highly effective vaccines against these 
diseases have proven difficult to develop and are not 
yet available. Although most licensed vaccines work by 
inducing efficacious antibody responses [2], data from 
numerous preclinical and clinical studies suggest that 
highly effective vaccines against these three pathogens 
may need to elicit strong T cell responses [3–9]. Adeno-
virus vectors are highly effective vaccine platforms for 
inducing potent  CD8+ T cell responses [10]. Therefore, 
adenovirus vectors represent attractive vaccine platforms 
for these pathogens.
CD8+ T lymphocytes are important mediators of pro-
tective immunity against the malaria liver stage [11–20]. 
A gene-based vaccine approach was developed based on 
findings that heterologous prime-boost immunization 
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induces  CD8+ T cells and protection against malaria in 
mice [21–24], non-human primates [25] and humans [5, 
6, 26–31]. Particularly encouraging data were obtained 
in a clinical study using a DNA prime-human adenovi-
rus serotype 5 (HuAd5) boost regimen expressing two 
malaria antigens, Plasmodium falciparum circumsporo-
zoite protein (PfCSP) and P. falciparum apical membrane 
antigen 1 (PfAMA1). In this study, 4 of 15 volunteers 
were sterilely protected against controlled human malaria 
infection (CHMI) [5].  CD8+ T cell responses specific for 
PfAMA1 were associated with protection, and two of the 
four protected volunteers had the highest frequency of 
 CD8+ T cell responses specific for PfCSP [5]. DNA prim-
ing was essential as the HuAd5 vectors alone failed to 
elicit protection [5, 32].
Although these results are encouraging, they do not 
meet the preferred product characteristics target of 75% 
efficacy set forth by the World Health Organization 
(WHO) [33]. One approach to improve vaccine efficacy is 
to identify more potent adenovirus vaccine vectors.
One factor that can affect the potency of an adenovi-
rus-based vaccine is pre-existing immunity against the 
adenovirus vector. HuAd5 is a relatively common human 
pathogen, with 35–50% seroprevalence in the USA and 
Europe and 70–95% seroprevalence in malaria-endemic 
regions of sub-Saharan Africa [34–39]. Pre-existing 
immunity against HuAd5 can affect the immunogenic-
ity and efficacy of HuAd5-based vaccines, reducing the 
percentage of responders and the frequency of T cell 
responses [40–42]. In the DNA-HuAd5 malaria trial, 50% 
of the volunteers with low (<12) HuAd5 pre-existing neu-
tralizing antibodies (NAb) titres were protected against 
CHMI, whereas none of the volunteers with high (>500) 
pre-existing NAb titres were protected [5]. Since the vast 
majority of malaria-related deaths occur in sub-Saharan 
Africa, where the HuAd5 seroprevalence is very high, 
pre-existing HuAd5 immunity could have a dramatic 
impact on the efficacy of a HuAd5-based malaria vaccine.
A second factor that can affect the potency of an ade-
novirus-based vaccine is the inherent capacity of specific 
adenovirus serotypes to induce immune responses to the 
encoded transgene. Most studies indicate that HuAd5 
and chimpanzee adenovirus type 3 (ChAd3) induce very 
robust transgene-specific immunity and that other lead-
ing adenovirus vectors are less immunogenic and less 
protective in animal models [39, 43–46]. These studies 
highlight the need for identifying new highly immuno-
genic adenovirus serotypes with low seroprevalence in 
human populations for vaccine development.
Three gorilla adenoviruses, GC44, GC45, and GC46, 
are being developed as vaccine vectors. Although the 
gorilla adenoviruses are closely related to human species 
C adenoviruses [47], they are not efficiently neutralized by 
human sera. Less than 6% of people living in the United 
States are seropositive for GC44, GC45 or GC46; and the 
few individuals who are seropositive have very low NAb 
titres against these viruses [38]. In this report, the immu-
nogenicity and efficacy of GC44, GC45 and GC46 vectors 
expressing the P. yoelii circumsporozoite protein (PyCSP) 
are described. One vector, GC46, was more efficacious 
than HuAd5 in this murine malaria model, suggesting that 
GC46 is a strong candidate for further malaria vaccine 
development.
Methods
Adenovirus seroprevalence and neutralizing antibody 
assay
NAb assays were performed as previously described [38] . 
In brief, serum samples from adults residing in the USA 
(n  =  250), Kenya (n  =  90) and Ghana (n  =  100) were 
diluted 1:16, incubated with HuAd5, GC44, GC45 and 
GC46 vectors expressing the firefly luciferase gene for 1 h 
at room temperature, and then used to infect 5 × 104 A549 
cells in triplicate at a multiplicity of infection (MOI) of 
2000 virus particle units (pu)/cell. Twenty-four hours post-
infection, the cells were lysed with Cell Culture Lysis Buffer 
(Promega, Madison, WI) and luciferase activity was meas-
ured using the Luciferase Assay Reagent System (Promega). 
Samples that resulted in >90% reduction in luciferase activ-
ity compared to the virus-only control were defined as pos-
itive for NAb. The positive samples were then diluted from 
1:32 to 1:1024 in twofold increments and tested for their 
capacity to neutralize the same set of vectors. The endpoint 
titre was defined as the maximum dilution at which the 
serum sample displayed a 90% reduction in luciferase activ-
ity compared to the virus-only control.
DNA and adenovirus vaccine vectors
Plasmid DNA vectors
The DNA-PyCSP vector (VR2516) was generated by 
cloning the native, full-length PyCSP gene into VR1020 
(Vical, San Diego, CA) [48]. This cloning reaction posi-
tions the PyCSP gene downstream from a human cyto-
megalovirus (HCMV) Immediate-Early (IE) promoter 
and in-frame with a human tissue plasminogen activa-
tor (TPA) signal sequence [48]. The DNA Null vector 
(VR1020) contains a TPA signal sequence, but does not 
contain a transgene. VR2516 and VR1020 were manu-
factured to preclinical grade specifications (Premium 
Research Ready plasmid DNA) by Puresyn, Inc. (Mal-
vern, PA).
Adenovirus vectors
The E1-, partial E3-, E4-deleted, replication-incompetent 
HuAd5-PyCSP vector and the E1-deleted, replication-
incompetent GC44-PyCSP, GC45-PyCSP and GC46-PyCSP 
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vectors were generated in ORF6 cells [49] using a plasmid-
based construction system that positions the PyCSP gene in 
the E1 region downstream from a HCMV IE promoter [24]. 
The HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP and GC46-
PyCSP vectors express a codon-optimized PyCSP gene in 
which the PyCSP glycosylphosphatidylinositol (GPI) anchor 
has been deleted. The HuAd5 Null and GC46 Null vectors 
do not express a transgene.
Mice and parasites
Six week old female BALB/c mice were purchased from 
either Harlan Laboratories (Frederick, MD) or the 
National Cancer Institute (Frederick, MD). Plasmodium 
yoelii (17XNL non-lethal strain) parasites were main-
tained by alternating passage in Anopheles stephensi mos-
quitoes and female CD1 outbred mice.
Female BALB/c mice were injected intramuscularly 
in the tibialis anterior muscle with 100  µl of vaccine 
(50 µl in each leg). The DNA vectors were prepared and 
diluted for immunization in 1× phosphate buffered 
saline (PBS). The adenovirus vectors were prepared and 
diluted for immunization in final formulation buffer 
[24]. In the single-dose immunogenicity study, 6 mice/
group were immunized with 1 × 107, 1 × 108 or 1 × 109 
pu of HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP, GC46-
PyCSP or HuAd5 Null. Twenty-one days post-immu-
nization, the mice were killed and splenocytes and sera 
harvested for evaluation of PyCSP-specific T cell and 
antibody responses.
In protection study 1, 20 mice/group were primed on 
day 0 with 100 µg of DNA-PyCSP (VR2516) and boosted 
on day 43 with 1  ×  109 pu of HuAd5-PyCSP, GC44-
PyCSP, GC45-PyCSP or GC46-PyCSP. On days 38 and 
52, the mice were bled and sera prepared for evaluation 
of PyCSP-specific antibody responses. On day 55, 6 mice/
group were killed and splenocytes harvested for evalu-
ation of PyCSP-specific T cell responses. On day 57, 14 
mice/group were challenged intravenously in the tail vein 
with 100 P. yoelii sporozoites isolated from the salivary 
glands of infected mosquitoes and diluted for challenge 
in M199 medium containing 5% normal mouse serum. 
On days 62–71, parasitaemia was evaluated by examining 
Giemsa-stained thin blood smears. In protection studies 
2 and 3, mice were boosted with HuAd5-PyCSP or GC46-
PyCSP, but not with GC44-PyCSP or GC45-PyCSP. Oth-
erwise, the experimental design of the three protection 
studies was similar. Each protection study contained a 
group of 20 naïve, non-immunized mice and a group of 
20 negative control mice that were primed with VR1020 
and boosted with GC46 Null. Mice were considered posi-
tive if blood stage parasites were observed in any blood 
smear. To gauge the severity of the challenge, an  ID50 was 
determined by challenging four groups of naïve BALB/c 
mice (6 mice/group) with four suboptimal doses of P. yoe-
lii sporozoites (33, 11, 3.7 or 1.2 sporozoites). (An  ID50, 
or infectious dose 50, represents the dose of sporozoites 
required to infect 50% of challenged mice.) From these 
infectivity control mice, an  ID50 for protection studies 1, 
2 and 3 was calculated to be 2.45 sporozoites, 3.4 sporo-
zoites and 3.4 sporozoites, respectively.
Splenocytes
Single cell splenocyte suspensions were prepared by 
gently crushing the spleen between a 70 µm cell strainer 
placed over a 50 ml conical tube and the flat end of a ster-
ile 3 ml syringe plunger while rinsing the cells with cold 
wash buffer (1× Hank’s Balanced Salt Solution without 
 Ca2+ and  Mg2+, with 0.5% FBS and 10 mM HEPES). The 
cell suspension was washed twice with wash buffer, then 
the cell pellet was resuspended in 5 ml of Red Blood Cell 
Lysis Buffer (Sigma-Aldrich, St. Louis, MO). Following 
a 3  min lysis, wash buffer was added to a final volume 
of 50  ml. The cell suspension was then pelleted, resus-
pended in 20  ml of R10 media (RPMI-1640 media with 
10% FBS, 1× GlutaMax™-1 Supplement and 1× Penicil-
lin–Streptomycin), passed through a second 70  µm cell 
strainer into a clean 50 ml conical tube, counted with a 
Guava PCA (EMD Millipore, Billerica, MA), pelleted 
and resuspended in R10 media at a final concentration of 
1 × 107 cells/ml.
Stimulator cells
Peptide-pulsed stimulator cells were prepared by puls-
ing A20.2J (Clone HB-98, ATCC, Manassas, VA) suspen-
sion cells (1 × 107 cells/ml) with peptides (20 µg/ml for 
peptides <10 amino acids and 100 µg/ml for peptides >10 
amino acids) for a minimum of 1  h with gentle mixing 
every 20 min. The peptide-pulsed A20.2J cells were irra-
diated in a Cobalt-60 irradiator (16,666 rad), washed with 
R10 media and resuspended in R10 media at a final con-
centration of 1.35 × 106 cells/ml for the ELISpot assays, 
or 1.5 × 106 cells/ml for the ICS assays. Additional pep-
tide was added to the cell suspension at a final concentra-
tion of 20 µg/ml.
IFN‑γ ELISpot
IFN-γ ELISpot responses were assessed with fresh sple-
nocytes in group pools (6 mice/group) in quadruplicate 
wells. Group pools were prepared by combining sple-
nocytes from the individual mice in equal ratios. Sple-
nocytes were stimulated with A20.2J cells pulsed with 
peptides encoding the PyCSP immunodominant  CD8+ 
T cell epitope (amino acids 280–288, SYVPSAEQI) [50] 
or the PyCSP  CD4+ immunodominant/nested  CD8+ 
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subdominant T cell epitopes (amino acids 57–70, KIYN-
RNIVNRLLGD) [50] (AnaSpec, Fremont, CA). Media 
alone, splenocytes stimulated with irradiated non-pulsed 
A20.2J cells and PMA/Ionomycin-stimulated spleno-
cytes served as assay controls. In brief, multiscreen 
MSHAS4510 plates (EMD Millipore) were coated with 
100  µl/well of a rat anti-mouse IFN-γ antibody (Clone 
R4-6A2, BD Biosciences, San Jose, CA) at a final concen-
tration of 10  µg/ml in 1× PBS, pH 7.2. The plates were 
washed 3 times with RPMI-1640 media and blocked with 
R10 media at 37 °C in 5%  CO2 for a minimum of 3 h. The 
blocking media were then removed and the splenocyte 
group pools were plated at 400,000, 200,000 and 100,000 
cells/well with 135,000 peptide-pulsed A20.2J stimula-
tor cells/well. The plates were incubated at 37  °C in 5% 
 CO2 for 40  h and washed 9 times with PBS-T buffer 
(1× PBS, pH =  7.2 with 0.01% Tween-20). Biotinylated 
rat anti-mouse IFN-γ antibody (clone XMG1.2, BD Bio-
sciences) at 1 µg/ml in 1× PBS, pH = 7.2 was then added 
and the plates were incubated for 3 h at room tempera-
ture. After 3 washes with PBS-T, the plates were incu-
bated for 1 h at room temperature with a 1:800 dilution 
of peroxidase-labeled streptavidin (KPL, Gaithersburg, 
MD) in 1× PBS, pH = 7.2. The plates were then washed 
3 times with PBS-T and 3 times with 1× PBS, pH = 7.2. 
The spots were developed with DAB Reagent Set (KPL) 
according to the manufacturer’s instructions. The spots 
were counted using an AID ELISpot Reader (Autoimmun 
Diagnostika, Strassberg, GER). Data analysis was done 
with Microsoft Excel 2008 for Mac (Microsoft, Redmond, 
WA) and GraphPad Prism v5.0c (GraphPad Software, La 
Jolla, CA).
Flow cytometry: intracellular cytokine (ICS) staining 
and cell phenotyping
Freshly isolated splenocytes from individual mice (6 mice/
group) were stimulated with A20.2J cells pulsed with pep-
tides encoding the PyCSP immunodominant  CD8+ T cell 
epitope (amino acids 280–288, SYVPSAEQI), the PyCSP 
 CD4+ immunodominant/nested  CD8+ subdominant T 
cell epitopes (amino acids 57–70, KIYNRNIVNRLLGD) 
or the influenza hemagglutinin  CD8+ T cell epitope 
(amino acids 332–340, TGLRNTPSI). Media, spleno-
cytes stimulated with irradiated non-pulsed A20.2J cells 
and PMA/Ionomycin-stimulated splenocytes served as 
assay controls. In brief, 1  ×  106 splenocytes from indi-
vidual mice and 1.5 × 105 peptide-pulsed A20.2J stimula-
tor cells were incubated for 6–8 h at 37 °C in 5%  CO2 in 
96-well round bottom plates. BD Golgi Plug™ (BD Biosci-
ence) was added 1 h into the incubation to block cytokine 
release. The plates were then wrapped in plastic wrap 
and stored at 4  °C overnight. The samples were stained 
for viability using the LIVE/DEAD® Fixable Blue Dead 
Cell Stain Kit for UV excitation from Molecular  Probes® 
(Life Technologies, Grand Island, NY) and blocked for 
non-specific staining using Mouse BD Fc Block™ (BD Bio-
sciences). For the single-dose immunogenicity study, the 
samples were surface-stained with the following antibod-
ies (fluorochrome): CD4—RM4-5(eFlur-450) (eBiosci-
ence, San Diego, CA) and CD8a—53-6.7(PerCP-Cy5.5) 
(BD Biosciences). Following separate fixation and per-
meabilization steps, the samples were stained intracel-
lularly with the following antibodies (fluorochrome): 
IFN-γ—XMG1.2(PE), TNF-α—MP6-XT22(APC), and 
IL-2—JES6-5H4 (Alexa488) (BD Biosciences). The data 
were acquired using a BD FACSCalibur E1610 equipped 
with a Cytek DxP Multi-Colour Upgrade (using 3 lasers to 
allow acquisition of 8 colours) and an Automated Micro-
Sampler (96 well format) (BD Biosciences). The samples 
for the prime-boost experiments were surface-stained 
with the following antibodies (fluorochrome): CD19—
1D3 (APC-H7), CD4—RM4-5(V500) (BD Biosciences), 
NKp46—29A1.4 (PerCP-e710) (eBioscience San Diego, 
CA), CD44—IM7(PE-Cy7), CD127—A7R34(BV421) and 
KLRG1—2F1/KLRG1(APC) (Biolegend, San Diego, CA). 
Following separate fixation and permeabilization steps, 
the samples were stained intracellularly with the following 
fluorochrome-labeled antibodies: CD8a—53-6.7(BV785), 
TNF-α—MP6-XT22(BV605) (Biolegend), CD3e-500A2 
(Alexa 700), IFN-γ—XMG1.2(Alexa 488) and IL-2—JES6-
5H4(PE) (BD Biosciences). The data were acquired using 
a BD LSR II equipped with 4 lasers and the automated 
96-well high throughput system (BD Biosciences). Pri-
mary data analysis was done with FlowJo v9.5.2 (Tree Star, 
Ashland, OR). Subsequent data analyses were done with 
Microsoft Excel 2008 for Mac and GraphPad Prism v5.0c.
ELISA
In the single-dose immunogenicity study, Immulon 4 
HBX flat-bottom microtitre plates (Dynex Technolo-
gies, Chantilly, VA) were coated overnight with purified 
PyCSP protein produced in yeast at a final concentra-
tion of 0.1  µg/ml. In the prime-boost protection stud-
ies, Immulon 4 HBX plates were coated with a synthetic 
peptide encoding a portion of the immunodominant 
PyCSP repeat region (QGPGAP)4 (AnaSpec) at a final 
concentration of 0.5  µg/ml (0.05  µg/well) in coating 
buffer (15 mM sodium carbonate, 35 mM sodium bicar-
bonate in UltraPure Water). The plates were blocked 
for 2 h with casein blocker in Tris buffered saline (TBS) 
(Pierce Thermo Scientific, Rockford, IL), washed with 1× 
TBS with 0.1% Tween-20 and incubated for 2 h at room 
temperature with threefold serial dilutions of sera from 
individual mice in triplicate wells. The plates were then 
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washed and incubated for 2  h with a 1:2000 dilution of 
ReserveAP phosphatase-labeled goat anti-mouse IgG 
(H + L), human serum absorbed (KPL) in Diluting Buffer 
(1× TBS with 0.1% BSA, 0.05% Tween-20). The plates 
were washed and developed with 0.1 mg/well of p-Nitro-
phenyl phosphate (Sigma-Aldrich) dissolved in Coating 
Buffer. The reaction was stopped by adding 25  µl/well 
of stop solution (5  N Sodium Hydroxide). Absorbance 
was measured at 405 nm using a SpectraMax 190 ELISA 
reader (Molecular Devices, Sunnyvale, CA) or a Spec-
traMax 340PC plate reader (Molecular Devices). Data 
analysis was done with Microsoft Excel 2008 for Mac and 
GraphPad Prism v5.0c.
Indirect immunofluorescent antibody (IFA)
Sporozoite stage IFAs were performed as previously 
described [51] using a fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse IgG antibody (KPL). End-
point dilutions were determined for individual mice, 
except for the negative control and naïve samples, where 
group pools were used. Endpoint dilution values repre-
sent the average of two separate assays.
Statistical analysis
Statistical analysis of the single-dose immunogenicity 
data was performed using one-way analysis of variance 
(ANOVA) followed by Bonferroni’s mean comparison test 
with Origin Pro 8.0 (OriginaLab, Northhampton, MA). 
Statistical analysis of the protection data was performed 
using a two-tailed Fisher’s Exact Test with GraphPad Prism 
v5.0c. Statistical analysis of the prime-boost ICS data was 
performed using a non-parametric, two-tailed, Mann–
Whitney U test with GraphPad Prism v5.0c. Statistical 
analysis of the prime-boost ELISA data was performed 
using an unpaired, two-tailed t test with GraphPad Prism 
v5.0c. Statistical analysis of the IFA data was performed 
using a two-tailed t test with GraphPad Prism v5.0c. P val-
ues of less than 0.05 were considered significant.
Results
Seroprevalence of GC44, GC45 and GC46 is low in humans 
living in Kenya and Ghana
Since the largest target population for a malaria vac-
cine resides in sub-Saharan Africa, the seroprevalence of 
GC44, GC45 and GC46 in sera samples from adults living 
in Kenya and Ghana were evaluated, and these outcomes 
were compared with the seroprevalence of HuAd5. Con-
sistent with results from the USA, the seroprevalence of 
the gorilla adenoviruses was much lower than HuAd5 in 
Kenya and Ghana (Fig.  1a). Moreover, in the few sero-
positive individuals, the NAb titres against GC44, GC45 
and GC46 were much lower than the NAb titres against 
HuAd5. Specifically, only 1–3% of individuals from 
both African countries had titres  >200 and none had 
titres >1000 (Fig. 1b, c). Overall, these results indicate a 
low prevalence of neutralizing antibodies to GC44, GC45 
and GC46 in malaria-endemic regions of sub-Saharan 
Africa, suggesting that they are suitable candidate vectors 
for malaria vaccine development.
Fig. 1 Seroprevalence of GC44, GC45 and GC46 in North American 
and African adults. a The seroprevalence (NAb titre >32) of HuAd5, 
GC44, GC45 and GC46 was determined in 250 adults living in the 
United States, 90 adults in Kenya and 100 adults in Ghana. In Kenya, 
the seroprevalence was 69, 20, 9 and 20% for HuAd5, GC44, GC45 and 
GC46, respectively. In Ghana, the seroprevalence was 91, 14, 14 and 
18% for HuAd5, GC44, GC45 and GC46, respectively. The NAb titres of 
individuals from Kenya (b) and Ghana (c) were segregated into four 
categories; <32, 32–200, 200–1000 or >1000. Higher NAb titres are 
represented by progressively darker colours. 16% of the Kenyan sam-
ples and 36% of the Ghanaian samples had NAb titres against HuAd5 
that were >1000, whereas none of the samples had comparable titres 
against GC44, GC45 or GC46. Additionally, 44% of the Kenyan samples 
and 77% of the Ghanaian samples had NAb titres against HuAd5 that 
were >200, whereas only 1, 1 and 3% of the Kenyan samples and 1, 1 
and 2% of the Ghanaian samples had comparable titres against GC44, 
GC45 and GC46
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GC44, GC45 and GC46 vectors expressing PyCSP induce 
robust PyCSP‑specific T cell and antibody responses 
in mice
To further evaluate the vaccine potential of the three 
gorilla adenoviruses, the immunogenicity of E1-deleted, 
replication-incompetent GC44, GC45 and GC46 vec-
tors that express PyCSP was evaluated in BALB/c mice 
(Fig. 2). Mice were immunized with three different doses 
of each vector. Positive control mice were immunized 
with comparable doses of a HuAd5-PyCSP vector and 
negative control mice were immunized with compara-
ble doses of a HuAd5 Null vector that does not express 
a transgene. Three weeks after immunization, PyCSP-
specific T cell and antibody responses were evalu-
ated by intracellular cytokine staining (ICS) and ELISA 
assays. Each GC-PyCSP vector induced strong PyCSP-
specific  CD8+ T cell and antibody responses (Fig. 2). At 
the two lower doses (1 × 107 and 1 × 108 pu), the three 
GC-PyCSP vectors each induced a higher percentage of 
IFN-γ-positive  CD8+ T cells than HuAd5-PyCSP. At the 
highest dose (1 ×  109 pu), the GC-PyCSP and HuAd5-
PyCSP vectors induced comparable responses (Fig.  2a). 
The GC-PyCSP vectors also induced higher antibody 
responses than HuAd5-PyCSP, especially at the 1 ×  109 
pu dose, where the differences were statistically signifi-
cant (p  <  0.05) (Fig.  2b). Overall, these results indicate 
that GC44, GC45 and GC46 are highly immunogenic and 
induce responses equal to or higher than HuAd5.
DNA‑GC46 vaccine is more efficacious than DNA‑HuAd5 
vaccine in the P. yoelii/mouse malaria model
The efficacy of the GC-PyCSP vectors was evaluated in 
the P. yoelii/mouse malaria model using a DNA-adeno-
virus prime-boost regimen. Three separate protection 
studies were performed. The general design of these 
studies is illustrated in Fig. 3. In the first study, all three 
GC vectors were compared with HuAd5. Since the high-
est levels of efficacy were achieved with GC46, this vector 
was selected for subsequent experiments (Table 1).
In study 1, the efficacy of the DNA-GC44 and DNA-
GC46 vaccines was slightly higher than the DNA-HuAd5 
vaccine, and much higher than the DNA-GC45 vaccine 
(Table 1). None of the 14 mice immunized with the DNA 
and GC46 Null vectors, and none of the 14 naïve mice 
were protected (Table 1). The protection induced by the 
DNA-HuAd5 vaccine (p =  0.0407), DNA-GC44 vaccine 
(p =  0.0159) and DNA-GC46 vaccine (p =  0.0058), but 
not the DNA-GC45 vaccine (p = 0.4815), was statistically 
significant compared to the negative controls.
To confirm the higher efficacy of the DNA-GC46 
vaccine relative to the DNA-HuAd5 vaccine, two fur-
ther studies were performed with the DNA-HuAd5 
and DNA-GC46 vaccines. In study 2, the efficacy of the 
DNA-HuAd5 vaccine was lower than in study 1 and was 
not statistically significant compared to the negative con-
trols (p = 0.4815). In contrast, the efficacy of the DNA-
GC46 vaccine was higher than the DNA-HuAd5 vaccine 
and was statistically significant (p = 0.0407) compared to 
Fig. 2 T cell and antibody responses induced by a single immuni-
zation of HuAd5-PyCSP, GC44-PyCSP, GC45-PyCSP or GC46-PyCSP. 
BALB/c mice (6 mice/group) were immunized with three different 
doses (1 × 107, 1 × 108 or 1 × 109 pu) of HuAd5 Null, HuAd5-
PyCSP, GC44-PyCSP, GC45-PyCSP or GC46-PyCSP. a  CD8+ T cell 
IFN-γ responses were assessed 21 days after immunization by ICS. 
Splenocytes were stimulated with A20.2J cells loaded with peptides 
encoding the PyCSP immunodominant  CD8+ T cell epitope (amino 
acids 280–288), the PyCSP immunodominant  CD4+/nested  CD8+ 
subdominant T cell epitopes (amino acids 57–70) or the influenza 
hemagglutinin  CD8+ T cell epitope (amino acids 332–240). Error bars 
indicate standard errors of the means (n = 6). *p <0.05 compared 
with HuAd5 at the same dose. b PyCSP-specific antibody responses 
were assessed 21 days after immunization by ELISA. The capture 
antigen was purified PyCSP protein. The values for individual mice 
are shown (n = 6). The mean is indicated by the black line. *p <0.05 
compared with HuAd5 at the same dose
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the negative controls. In study 3, the efficacy of the DNA-
HuAd5 vaccine was also low and was not statistically 
significant (p  =  0.2222) compared to the negative con-
trols. The efficacy of the DNA-GC46 vaccine, however, 
was very high (93% protection) and was highly statisti-
cally significant (p  <  0.0001) compared to the negative 
controls.
In each study, the DNA-GC46 vaccine protected a 
higher percentage of mice than the DNA-HuAd5 vac-
cine, however the difference was most striking in study 
3. When the data from all three studies were combined, 
the DNA-HuAd5 vaccine protected 10 of 42 mice (24% 
protection), while the DNA-GC46 vaccine protected 25 
of 42 mice (60% protection). The protection induced by 
the DNA-HuAd5 vaccine (p  =  0.0011) and the DNA-
GC46 vaccine (p < 0.0001) were both statistically signifi-
cant compared to the negative controls. Moreover, when 
compared to each other, the efficacy of the DNA-GC46 
vaccine was significantly higher than the DNA-HuAd5 
vaccine (p  =  0.0018). All of the vaccine groups also 
showed a modest delay to patency relative to the negative 
controls (Fig. 4). The time to patency, however, was not 
significantly different between the vaccine groups. These 
findings demonstrate that the GC46 vector conferred a 
higher level of protection than the HuAd5 vector.
DNA‑GC vaccines induce robust T cell and antibody 
responses in mice
The immunogenicity outcomes of protection study 1 are 
presented in Fig.  5. The PyCSP-specific cellular immune 
responses were assessed from splenocytes harvested 
12  days after the adenovirus boost using IFN-γ ELISpot 
and ICS by flow cytometry. The IFN-γ ELISpot response 
to stimulation with the PyCSP  CD4+ immunodominant/
nested  CD8+ subdominant epitopes (amino acids 57–70) 
were very low (mean < 50 sfc/m) in all four vaccine groups 
(Fig. 5a). In contrast, the responses to stimulation with the 
Fig. 3 Design of DNA prime-Ad boost protection studies. On week 0, 
BALB/c mice (20 mice/group) were primed with 100 µg of DNA-
PyCSP. On week 6, the mice were boosted with 1 × 109 pu of HuAd5-
PyCSP, GC44-PyCSP, GC45-PyCSP or GC46-PyCSP (protection study 
1), or 1 × 109 pu of HuAd5-PyCSP or GC46-PyCSP (protection studies 
2 and 3). Five days before (study day 38) and 9 days after (study 
day 52) the adenovirus boost, the mice were bled and sera isolated 
for antibody studies. Twelve days after the boost, 6 mice/group were 
euthanized and splenocytes isolated for T cell studies. On week 8, 
14 mice/group were challenged with 100 P. yoelii sporozoites. Blood 
stage parasitaemia was evaluated 5–14 days post-challenge
Table 1 Efficacy results
a The number and percentage of mice protected in each study, as well as the total number and percentage of mice protected in all three studies is presented. 
Statistical analyses (two-tailed Fisher’s Exact Test) utilized data from all three studies (n = 42)b or data from protection study 1 (n = 14)c
Vaccine Protectiona
Protected mice/total mice (% protected)
Statistical analyses
p value
Study 1 Study 2 Study 3 Total Total vs.  
Null
Total vs. 
DNA‑
HuAd5
DNA-HuAd5 5/14 (36%) 2/14 (14%) 3/14 (21%) 10/42 (24%) 0.0011b –
DNA-GC44 6/14 (43%) – – 6/14 (43%) 0.0159c 1.000c
DNA-GC45 2/14 (14%) – – 2/14 (14%) 0.4815c 0.3845c
DNA-GC46 7/14 (50%) 5/14 (36%) 13/14 (93%) 25/42 (60%) <0.0001b 0.0018b
Null 0/14 (0%) 0/14 (0%) 0/14 (0%) 0/42 (0%) –
Naïve 0/14 (0%) 0/14 (0%) 0/14 (0%) 0/42 (0%)
Fig. 4 Time to patency in protection studies 1–3. Patency data from 
all three protection studies is presented in a Kaplan–Meier graph. 
Parasitaemia was evaluated on days 5, 6, 7, 9 and 14 post-challenge. 
Thirty fields, representing approximately 30,000 red blood cells (RBC), 
were examined for each slide. A mouse was considered positive if a 
single parasitized RBC was observed
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PyCSP immunodominant  CD8+ T cell epitope (amino 
acids 280–288) were much higher (mean >1200 sfc/m) in 
all four vaccine groups. The IFN-γ ELISpot responses in 
the DNA-HuAd5 and DNA-GC46 groups were particularly 
robust, with mean spot forming cells and standard devia-
tions of 1793 ± 74 and 1604 ± 198 sfc/m, respectively.
Further phenotypic and functional analysis of indi-
vidual animals by ICS confirmed that the primary T cell 
populations responding to PyCSP 280–288 peptide stim-
ulation were antigen-experienced  CD8+ T cells  (CD3+/
CD8+/CD44+ “bright”) expressing IFN-γ (IFN-γ+/IL-2−/
TNF-α−) or IFN-γ and TNF-α (IFN-γ+/IL-2−/TNF-α+) 
(Fig. 5b). Much lower frequencies of triple positive (IFN-
γ+/IL-2+/TNF-α+) and IFN-γ/IL-2 double positive (IFN-
γ+/IL-2+/TNF-α−)  CD8+ T cells were observed. Overall, 
the frequency of the observed subsets was comparable in 
all vaccine groups, except that the DNA-GC46 vaccine 
induced a robust, but significantly lower frequency of IFN-
γ+/IL-2−/TNF-α+  CD8+ T cells than the DNA-HuAd5 
vaccine (DNA-GC46: 5.24%  ±  2.09%; DNA-HuAd5: 
9.42  ±  0.92%; p  =  0.0043). Consistent with the IFN-γ 
ELISpot data, multifunctional T cell analysis indicated 
that cytokine expression from  CD4+ T cells was negligible 
after stimulation with the PyCSP  CD4+ immunodominant 
epitope (amino acids 57–70) (Additional file 1).
Total IgG antibody responses to the PyCSP repeat 
region (QGPGAP)4 were assessed by ELISA with sera 
collected five days before (study day 38) and nine days 
after (study day 52) the adenovirus boost. In all four vac-
cine groups, responses were low after the DNA prime, 
but increased approximately 100-fold following the ade-
novirus boost (Fig. 6a). Following the adenovirus boost, 
the mean antibody titre of the DNA-HuAd5 group was 
higher than the titres of the DNA-GC groups although 
the differences were not statistically significant. IFA 
responses against P. yoelii sporozoites were evaluated 
with post-adenovirus boost sera. All four vaccine groups 
induced antibodies that recognized native P. yoelii para-
sites (Fig. 6b). In general, IFA titres were comparable in 
all vaccine groups.
Discussion
The WHO has estimated that approximately 429,000 
people died from malaria in 2015 [52]. Despite decades 
of effort, a highly effective malaria vaccine is not avail-
able. The leading vaccine candidate, RTS,S, has modest 
efficacy against clinical malaria in children and infants 
living in Africa [53, 54]. However, after 4 years, efficacy 
slowly wanes to zero [55, 56]. Based upon these results, 
new approaches are needed to meet the preferred prod-
uct characteristics target of 75% efficacy [33].
Vector-based prime-boost vaccines are a compelling 
approach for malaria vaccine development. In addi-
tion to the positive protection data obtained with the 
DNA-HuAd5 vaccine candidate [5], a prime-boost regi-
men with chimpanzee adenovirus type 63 (ChAd63) 
and modified vaccinia Ankara (MVA) vectors expressing 
PfCSP or a P. falciparum thrombospondin-related adhe-
sion protein construct with a multi-epitope (ME) string 
of 17 P. falciparum B cell and T cell epitopes (PfME-
TRAP) protected a total of 1 of 15 or 5 of 29 volunteers, 
Fig. 5 T cell responses induced by the prime-boost vaccines in 
protection study 1. IFN-γ ELISpot and ICS responses were assessed 
12 days after the adenovirus boost. a IFN-γ ELISpot. Splenocytes from 
group pools (200,000 cells/well) were stimulated with A20.2J cells 
loaded with peptides encoding the PyCSP immunodominant  CD8+ T 
cell epitope (amino acids 280–288) or the PyCSP  CD4+ immunodomi-
nant/nested  CD8+ subdominant T cell epitopes (amino acids 57–70). 
Spot forming cells (SFC)/1 × 106 splenocytes are presented. Bars 
represent the mean ± standard deviation from quadruplicate wells.  
b ICS. Splenocytes from individual mice (6 mice/group) were 
stimulated with A20.2J cells loaded with a peptide encoding the 
PyCSP immunodominant  CD8+ T cell epitope. Boolean gating was 
used to define the frequency of antigen-experienced  CD8+ T cells 
 (CD19−/NKp46−/CD3+/CD8+/CD44+ “bright”) expressing IFN-γ, IL-2 
and/or TNF-α. The line within the box represents the mean and the 
bottom and top lines of the box represent the minimum and maximum 
responses observed in individual mice. **indicates statistical signifi-
cance compared with the DNA-HuAd5 vaccine
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respectively, against CHMI [6, 57]. In a Phase 2b trial, the 
ChAd63-MVA PfME-TRAP vaccine reduced the risk of 
malaria infection in Kenyan adults by 67% during the first 
8  weeks post-immunization [58]. Although this vaccine 
does not meet the 75% efficacy target, these results are 
very encouraging and suggest that a non-human primate 
adenovirus vector can be a component of an efficacious 
malaria vaccine.
The major rationale for this study was to develop highly 
potent adenovectors with low human seroprevalence 
as an alternative to HuAd5, as high seroprevalence in 
malaria-endemic countries may compromise the efficacy 
of a HuAd5-based vaccine. The data presented in this 
report support the development of three new adenovirus 
vaccine vectors, GC44, GC45 and GC46. These vectors 
were isolated from wild gorillas in Rwanda and cluster by 
phylogeny in the same subgroup (species C adenoviruses) 
as two other potent vaccine vectors, HuAd5 and ChAd3. 
The results presented indicate that the seroprevalence of 
NAb specific for GC44, GC45 and GC46 are low in Kenya 
and Ghana, two malaria-endemic countries in sub-Saha-
ran Africa. In fact, only 1–3% of adults living in Kenya 
and Ghana have NAb titres against GC44, GC45 or GC46 
that are  >200, a titre that has been shown to affect the 
potency of HuAd5-based vectors in previous clinical tri-
als [41]. Moreover, since the seroprevalence and NAb 
titres against adenoviruses are lower in children than 
adults [37], pre-existing immunity should not affect the 
potency of GC-based vaccines in pediatric populations.
The superior performance of GC46 over HuAd5 high-
lights its potential for malaria vaccine development. Effi-
cacy studies in the P. yoelii/mouse model indicated that a 
prime-boost regimen with DNA-PyCSP and GC-PyCSP 
vectors could protect mice against a P. yoelii challenge. 
GC46 was more protective than HuAd5 in three separate 
experiments and when analysed together, the efficacy of 
GC46 was significantly higher than HuAd5 (p > 0.0018). 
Typical of complex biological systems, overall efficacy 
levels varied between experiments. Results also indicated 
that the GC-PyCSP vectors are more immunogenic than 
HuAd5-PyCSP following a single immunization. At the 
lower doses, the three GC-PyCSP vectors all induced 
higher  CD8+IFN-γ+ T cell responses than HuAd5-
PyCSP, and at the highest dose, the three GC-PyCSP 
vectors all induced higher antibody responses than 
HuAd5-PyCSP. GC46-PyCSP, in particular, was highly 
immunogenic, inducing greater T cell and antibody 
responses than HuAd5-PyCSP at all doses. Similar results 
were obtained with GC44, GC45 and GC46 vectors 
expressing respiratory syncytial virus (RSV) [38], herpes 
simplex virus 2, Epstein Barr virus, and other malaria 
antigens (unpublished data). These results highlight the 
versatility of these new gorilla adenovirus vectors for vac-
cine development.
Previous studies with DNA and adenovirus-based vac-
cines in the P. yoelii/mouse model have indicated that 
protection is dependent on  CD8+ T cells [16, 22].  CD8+ 
T cell responses have also been associated with the pro-
tection elicited by the DNA-HuAd5 and ChAd63-MVA 
malaria vaccines in humans [5, 6]. The GC-PyCSP vec-
tors evaluated in this report all induced robust  CD8+ T 
cell responses after priming with DNA. Phenotypic and 
multifunctional analysis identified antigen experienced 
Fig. 6 Antibody responses induced by the prime-boost vaccines in 
protection study 1. a ELISA. PyCSP-specific antibody responses (14 
mice/group) were assessed on study day 38 (SD38) and study day 52 
(SD52), 5 days before and nine days after the adenovirus boost. Plates 
were coated with a peptide encoding a portion of the immunodomi-
nant PyCSP repeat region (QGPGAP)4. The data are presented as a 
box-and-whisker plot. The line within the box represents the median, 
the bottom and top lines of the box represent the 25th and 75th per-
centiles, the whiskers represent the 10th and 90th percentiles and the 
dots represent outliers. The lowest dilution assayed was 1/50. b IFA. 
PyCSP-specific antibody responses (14 mice/group) were assessed on 
day 52, 9 days after the adenovirus boost. The data are presented as a 
box-and-whisker plot. The median and upper box lines overlap in the 
DNA-HuAd5 data and the median and lower box lines overlap in the 
DNA-GC44 data. The lowest dilution assayed was 1/40
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 CD8+IFN-γ+ T cells or  CD8+IFN-γ+TNF-α+ T cells 
as the primary cellular subsets responsible for this 
response. Interestingly, the only significant immuno-
logical difference observed between the DNA-HuAd5 
and DNA-GC46 regimens was in the frequency of 
 CD8+IFN-γ+TNF-α+ T cells. These analyses suggest that 
immune parameters other than IFN-expressing  CD8+ T 
cells may be involved in protective immunity. Overall, the 
DNA-GC46 vaccine induced robust  CD8+ IFN-γ+ T cell 
and antibody responses, as well as consistently significant 
protection, thereby indicating that GC46 is a compelling 
alternative to HuAd5 for clinical development.
The capacity of the GC vectors to induce robust and 
protective immune responses suggests that GC vectors 
belong to a select group of adenovirus vectors that are 
at least on par with HuAd5 in terms of potency. These 
results are encouraging because most adenovirus vectors, 
with the exception of ChAd3, are less immunogenic than 
HuAd5 [39, 43–46]. For example, preclinical data demon-
strate that a single administration of 1 × 1010 viral parti-
cles of a ChAd3-Ebola virus vector protected macaques 
from Ebola virus challenge [46]. This is similar to what 
has been observed with a HuAd5-Ebola virus vector 
[59]. Importantly, none of the other leading adenovectors 
(human adenovirus serotype 35, human adenovirus sero-
type 26 or ChAd63) were capable of providing this high-
level protection [44, 46]. As a result, ChAd3 is currently 
being tested in clinical trials as a vaccine vector for Ebola 
virus and hepatitis C virus (HCV) [60–63].
Conclusions
The low seroprevalence, robust immunogenicity and 
enhanced efficacy of GC46 vectors relative to HuAd5 vec-
tors suggest that this gorilla-based adenovector has key 
performance characteristics for an effective malaria vac-
cine. A DNA-GC46 malaria vaccine may be more effica-
cious than a DNA-HuAd5 malaria vaccine in humans, 
especially those individuals with high HuAd5 NAb titres. 
Additional efficacy, if needed, could potentially be obtained 
by incorporating new protective antigens into the vaccine 
[6, 64] or by improving the immunogenicity of the individ-
ual DNA or adenovirus vaccine components [65, 66].
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